Tag Archives: Mural Oncology

Elahere (MIRV) keeps quality of life stable – new analysis of the MIRASOL study

Elahere (MIRV) keeps quality of life stable
- new analysis of the MIRASOL study

New results of the MIRASOL study were published in April 2025.

The study results showed that the drug mirvetuximab soravtansine-gynx (trade name Elahere) prolonged the time to disease progression and overall survival in patients with platinum-resistant ovarian cancer with high levels of the folic acid receptor α (FRα).

Focus on quality of life

The latest data from the study assess quality of life from the patient’s perspective (patient-reported outcomes).

This showed that Elahere can neither worsen nor clearly improve quality of life compared to conventional chemotherapy. There were slight indications of benefits, particularly for abdominal and digestive complaints: 21% of patients taking Elahere reported noticeable improvements – compared to 15% taking chemotherapy, although the difference was not entirely statistically certain. Nevertheless, in a follow-up analysis with other measurements, there were indications of actual improvements in up to 29% vs. 18%.

What does that mean in concrete terms?

  • No deterioration in quality of life: Women undergoing therapy with Elahere reported similar living conditions to those with standard therapy.

  • Symptoms remain stable: important everyday symptoms such as pain or appetite did not deteriorate.

  • Combination of efficacy and stability: Since Elahere has also been shown to prolong survival, it now offers a promising treatment option – without the additional burden of poor quality of life.

Why is this relevant?

  • Effective & well-tolerated treatment: Elahere not only postpones the disease, but also has no negative impact on patients’ everyday lives.

  • New option for a difficult-to-treat situation: There are only a few effective treatment options for platinum-resistant ovarian cancer – Elahere adds a solid option to this field.

Source: The Lancet Oncology (the article is in English)

No effect on ovarian cancer: development of Nemvaleukin is stopped

No effect on ovarian cancer:
Development of Nemvaleukin is stopped

In March 2025, Mural Oncology released disappointing news for patients with platinum-resistant ovarian cancer.

The international phase 3 ARTISTRY-7 trial investigated whether a combination of two immunotherapies – nemvaleukin and pembrolizumab – is more effective than standard chemotherapy. Unfortunately, an interim analysis showed that the combination therapy did not prolong patient survival compared to chemotherapy.

The mean survival time was 10.1 months in the immunotherapy group and 9.8 months in the comparison group – a very small and therefore not statistically relevant difference. The study was therefore stopped prematurely and the development of the drug for this form of cancer was discontinued.

What is Nemvaleukin?

Nemvaleukin is an experimental drug that was originally developed to specifically activate the immune system against tumor cells – without the strong side effects of conventional immune activators. It has already been tested in several studies, including in black skin cancer (melanoma). There, too, the hoped-for therapeutic successes failed to materialize.

Consequences: Company discontinues development

A few weeks after the initial results, Mural Oncology announced that it would discontinue all clinical development of Nemvaleukin – including for other types of cancer such as melanoma. At the same time, the company is planning a drastic restructuring in terms of job cuts and possibly a sale or merger with another company.

Significance for patients

For patients with platinum-resistant ovarian cancer, treatment remains a major challenge – new options are urgently needed. Despite this disappointment, the study is an important contribution to a better understanding of why some cancers, such as ovarian cancer, respond so poorly to immunotherapies.

Source: Mural Oncology press release 1 and press release 2 (the articles are in English)